US FDA approves Remicade in paediatric UC
This article was originally published in Scrip
Executive Summary
Johnson & Johnson unit Janssen Biotech has secured FDA approval for the use of Remicade (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in children who have had an inadequate response to conventional therapy, making it the first biologic treatment available in the US for this expanded indication.